linjc16/ctgov huggingface dataset:
Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China

Study Overview
=================
Brief Summary
-----------------
Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). It is reported that over half of COPD patients develop pulmonary hypertension. COPD and pulmonary hypertension may have pathological or genetics interactions so that patients having both disorders tend to have poor prognosis. Echocardiography is widely used to detect pulmonary hypertension, but it's not accurate enough. Therefore, high-quality data reflecting the prevalence, disease course and outcome of pulmonary hypertension in COPD is very limited in China. The aim of the study is to detect pulmonary hypertension with right heart catheterization, describe its outcome in Chinese COPD patients and explore the underlying interaction mechanism.

Official Title
-----------------
The Prevalence, Disease Course, Prognosis and Interaction of Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension

Conditions
-----------------
COPD, Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable chronic obstructive pulmonary disease (COPD) patients Exclusion Criteria: Patients with other serious respiratory diseases Patients with pulmonary hypertension other than group 3 Patients with right heart hypertrophy or dysfunction not caused by chronic obstructive pulmonary diseases Patients with limited life expectancy Patients with history of tracheal intubation or stoke, acute coronary syndrome in 6 months Psychopath or addict

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| COPD exacerbations | total hospitalizations times due to COPD exacerbations | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| modified British medical research council (mMRC) score | COPD symptom score | 3 years | 
| COPD Assessment Test (CAT) score | COPD symptom score | 3 years | 
| 6 minutes walk distance | meters | 3 years | 
| transplant-free survival rate | transplant-free survival rate in % | 3 years |
Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome

Study Overview
=================
Brief Summary
-----------------
Polycystic ovary syndrome accounts for the vast majority of anovulatory symptoms and hyperandrogenism in women. The diagnosis of Polycystic ovary syndrome has life-long implications, with increased risk for infertility, metabolic syndrome, and type 2 diabetes mellitus, and possibly for cardiovascular disease and endometrial carcinoma. Polycystic ovary syndrome is diagnosed in adolescents with otherwise unexplained, persistent hyperandrogenic anovulatory symptoms that are inappropriate for age and stage of adolescence. It should be considered in any adolescent girl with a chief complaint of hirsutism, treatment-resistant acne, menstrual irregularity, acanthosis nigricans, and/or obesity

Official Title
-----------------
Efficacy of Combined Letrozole-metformin in Comparison With Letrozole Only in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Drug: letrozole plus metformin
* Drug: letrozole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: polycystic ovaries patients who had failed to become pregnant after 3 courses of 150 mg of clomiphene citrate (considered as clomiphene resistant),whereas the value of the above mentioned investigation are normal. Exclusion Criteria: women with other causes of infertility as male factor,tubal factor,those with endocrine disorders as thyroid dysfunction and hyperprolactinemia. women who received hormonal treatment or ovulation induction drugs in the last 3 months before the study. women with history of liver,kidney or cardiovascular disease.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: letrozole plus metformin<br>5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding plus metformin will be started from the first day with a dose of 850 mg (1 tablet daily) and the dosage will be increased after 1 week up to 1,700 mg/day (2 tablets daily) and will be continued | Drug: letrozole plus metformin<br>* letrozole 5 milligram tablets plus metformin 850 milligram tablets<br>|
| Active Comparator: letrozole<br>5 mg of letrozole will be administered only for 5 days from day 3 each month of spontaneous or induced bleeding | Drug: letrozole<br>* letrozole 5 milligram tablets<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The ovulation rate |  | 14 days |
The Immune Response to Stroke

Study Overview
=================
Brief Summary
-----------------
Some patients develop cognitive decline after a stroke, but we don't always understand the mechanisms. It has been proposed that a proportion of the patients develop an autoimmune immune response, and that this could potentially explain the cognitive decline in some of the patients. The current study aims to investigate this hypothesis in a subgroup of patients with stroke.

Official Title
-----------------
The Immune Response to Stroke

Conditions
-----------------
Stroke, Acute, Dementia

Intervention / Treatment
-----------------
* Other: Analysis of post-stroke immune responses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stroke < 72 h Age > 18 years Exclusion Criteria: Brain hemorrhage verified by CT or MRI scan Previous or present immunological disease or other serious comorbidity Ongoing immune respons after infection or vaccination < 1 month Cognitive without ability to understand and/or give an informed consent to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stroke patients<br> | Other: Analysis of post-stroke immune responses<br>* Analysis of immune responses in peripheral blood<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The B cell and T cell response in peripheral blood |  | 1 day (subject inclusion) |
Confirmation of Nasogastric Tube Placement Via Ultrasonography

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine if ultrasonography is an adequate means for confirmation of nasogastric tube placement and that ultrasonography is more time efficient than radiography confirming nasogastric tube placement.

Detailed Description
-----------------
Our current nasogastric tube placement protocol requires confirmation of nasogastric tube placement with plain radiography. Obtaining a plane radiograph in the emergency department can be time consuming and exposes the patient to radiation. Ultrasound is readily available to our physicians and does not expose patients to radiation. Confirmation of nasogastric tube placement by ultrasonography may provide a faster means of confirmation and expose patients to less radiation.

Official Title
-----------------
Confirmation of Nasogastric Tube Placement Via Ultrasonography

Conditions
-----------------
Nasogastric Tube Intubation

Intervention / Treatment
-----------------
* Other: Ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female Patients 18 years of age or older. Patients in the emergency department at Oklahoma State University Medical Center that require NG intubation with radiography confirmation. Exclusion Criteria: Patients under the age of 18 years of age. Patients that are prisoners of the State or Government. Patient is pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasonography is as accurate as plain radiograph in confirming nasogastric tube placement |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasogastric tube verification with ultrasonography, ultrasonography
Perspectives on End-of-Life Care for Medically-Fragile Children and Young Adults

Study Overview
=================
Brief Summary
-----------------
Hattie Larlham is a specialized long-term care facility for pediatric and young adult residents who are medically fragile and intellectually disabled, whose daily care is provided by direct care staff, Habilitation Assistants (HA), in conjunction with nurses and other direct care providers. The purpose of this study is to assess the perspectives of HA and parents/legal guardians on end-of-life care in a long-term care facility for pediatric and young adult residents who are medically fragile and intellectually disabled.

Official Title
-----------------
Direct Care Staff and Parents'/Legal Guardians' Perspectives on End-of-Life Care in a Long-Term Care Facility for Medically Fragile and Intellectually Disabled Pediatric and Young Adult Residents

Conditions
-----------------
Death

Intervention / Treatment
-----------------
* Other: Survey
* Other: Focus group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HA at Hattie Larlham between January 1, 2006 to present HA provided care to > 1 resident whose death occurred between January 1, 2006 through the end of the study period HA provided ongoing care to the resident for at least 5 days in the last 30 days at Hattie Larlham before the resident's death Parent/legal guardian of a Hattie Larlham resident whose death occurred between January 1, 2006 through the end of the study Exclusion Criteria: HA employed < 30 days at Hattie Larlham or cared for resident <5 days in last 30 days prior to the resident's death HA or parent/legal guardian who has not experienced a Hattie Larlham resident's death since December 31, 2005
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Habilitation assistants | Other: Survey<br>* 3 individual surveys<br>Other: Focus group<br>* Focus group discussions facilitated by a psychologist<br>|
| 2<br>Parents/ legal guardians | Other: Survey<br>* 3 individual surveys<br>Other: Focus group<br>* Focus group discussions facilitated by a psychologist<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants' responses to survey questions. |  | Start of Study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Participants' responses to focus group discussions. |  | End of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
parents, medically fragile, death, end-of-life care, surveys
Return to Work After Total Knee Arthroplasty in Young Patients

Study Overview
=================
Brief Summary
-----------------
This study takes its base in the augmenting number of primary total knee arthroplasty in the world whom quality and survey had permit to widen their indications to younger patients who are in the age of professional activity. This work will focus on young patients under 55 who had had primary total knee arthroplasty, retrospectively, over the past 10 years, to determine the factors influencing early or late return to work, depending of socio economics factors. This will optimize the information for the patient, and prepare him if necessary for a long work stop, and possibly obtain a better satisfaction for him.

Detailed Description
-----------------
The primary aim of this study is to determine the rate of young patients returning to work after a primary total knee arthroplasty and the mean delay, and to compare it to other studies. The mean delay of return to work in the literature is between 8 to 12 weeks, with up to 98% of patients returning to work. The investigators will next determine which category of patients could have a late return to work superior to 6 months, and also if the surgery could give back a professional activity to patients who were in a long work stoppage.

Official Title
-----------------
Return to Work After Total Knee Arthroplasty in Patients Under 55, a Retrospective Study in an University Hospital

Conditions
-----------------
Knee Arthritis

Intervention / Treatment
-----------------
* Procedure: Total knee arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: first intention total knee arthroplasty Age at the time of surgery under 55 Exclusion Criteria: Not in capacity of completing a questionnaire revision of total knee arthroplasty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| total knee arthroplasty under 55<br>Patient who had total knee arthroplasty before 55 between January 2010 and December 2019 | Procedure: Total knee arthroplasty<br>* First intention total knee arthroplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Return to work in weeks | Duration between surgery and return to work | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
total knee arthroplasty, return to work, arthroplasty
Performance Developement of Patients With Paraplegia During First Rehabilitation

Study Overview
=================
Brief Summary
-----------------
A high physical fitness is crucial for a good quality of life in persons suffering from a spinal cord injury. The aim of the present observational study is to investigate the influence of an individually tailored 8-week endurance training program on endurance performance of patients with a paraplegia during their first rehabilitation.

Official Title
-----------------
Effects of an Individually Tailored Endurance Training on the Performance Developement of Patients With Paraplegia During First Rehabilitation: an Observational Study

Conditions
-----------------
Physical Activity

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent male or female, paraplegia (AIS A-C, lesion Level Th1-Th12) Age 18-65 years Manual wheelchair user Patient during first rehabilitation Exclusion Criteria: BMI ≥ 30 unable to use an arm-crank Ergometer due to e.g. spasticity physical impairment, which makes it impossible to perform an arm-crank ergometry Progressive disease (g.g. tumor, MS) Ventilator dependent existing cardiopulmonary disease Unstable medical situation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Peak power | Maximal performance reached during incremental exercise on an arm-crank ergometer | 10min |
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy

Study Overview
=================
Brief Summary
-----------------
Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months oral anticoagulation therapy after operation. However, a small part of patients still suffered thrombotic events after withdrawal of warfarin, which means these patients may need extend anticoagulation therapy. D-dimer, a sensitive marker of thrombosis or prethromboembolism state. Previous studies have demostrated that patients with elevated D-dimer levels have significant more clinical outcomes than those with nagative D-dimer levels. The aim of this study was to evaluate whether D-dimer could guide the duration of oral anticoagulation therapy in patients with BHV.

Detailed Description
-----------------
Patients with BHV were screened and enrolled in this study. D-dimer levels were measured in the sixth months after BHV operation but before withdrawal of warfarin. Patients with elevated D-dimer were randomized to extend anticoagulation therapy group and routine stopping anticoagulation group.

Official Title
-----------------
Randomized Evaluation of D-dimer Guiding Duration of Oral Anticoagulation Therapy in Patients With Bioprosthetic Heart Valves

Conditions
-----------------
Valve Heart Disease, Anticoagulants; Increased

Intervention / Treatment
-----------------
* Drug: Warfarin Sodium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients received BHV within 3 months Exclusion Criteria: Recently throboemblism within 6 months Recently bleedings within 3 months Evaluated lifetime less than 2 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Extend anticoagulation group<br>Extended the duration anticoauglation to 12 months | Drug: Warfarin Sodium<br>* Extending warfarin anticoagulation<br>|
| No Intervention: Stop anticoagulation group<br>Just stop oral anticoagulation like routine | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombotic events | Stroke, DVT, PE, valve thrombosis | 24 months | 
| Bleeding events |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bioprosthetic heart valves, oral anticoagulation, thrombotic events
Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

Study Overview
=================
Brief Summary
-----------------
Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Trazodone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with akathisia according to DSM-IV criteria at least mild akathisia. Exclusion Criteria: Change of pharmacologic regimen 7 days prior to study entry Significant systemic disease The presence of chronic akathisia Patients unable to cooperate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>The patients in this arm received placebo | Drug: Placebo<br> <br> |
| Active Comparator: Trazodone<br>The patients on this arm received Trazodone for 3 consecutive days | Drug: Trazodone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barnes Akathisia rating scale, Positive and Negative syndrome scale, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms |  |  |
Post Transplant Study

Study Overview
=================
Brief Summary
-----------------
Retrospective chart review to gather information on Sensipar patterns of use and effects on biochemical parameters in renal transplant recipients

Official Title
-----------------
A Retrospective Evaluation of Sensipar Use in Renal Transplant Recipients

Conditions
-----------------
Kidney Tansplant, Secondary Hyperparathyroidism, Hyperparathyroidism

Intervention / Treatment
-----------------
* Drug: Sensipar after Post Transplant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults >= 18 years old Subjects who have received Sensipar for a duration of at least 3 months, beginning at least 3 months after a kidney transplant. Subjects must have begun Sensipar teatment no later than Februry 28, 2005 at treating physician's discretion. Exclusion Criteria: Subjects who received Sensipar before undergoing a kidney transplant Subjects receiving dialysis post-transplant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sensipar after Post Transplant|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sensipar, cinacalcet, Mimpara